Form 4: Apogee Insider Sells $133.5M Shares Under 10b5-1 Plan

Fairmount Funds Management and associated directors plan to sell 1.75 million shares of Apogee Therapeutics common stock at $76.3 per share under a pre-arranged trading plan.

Summary

• Fairmount Funds Management LLC, a 10% owner and investment manager for Fairmount Healthcare Fund II L.P., along with directors Tomas Kiselak and Peter Harwin, reported a planned disposition of Apogee Therapeutics, Inc. common stock.
• The transaction involves the sale of 1,750,000 shares of common stock at a price of $76.3 per share, scheduled for January 22, 2026.
• This sale is being conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following the transaction, Fairmount Healthcare Fund II LP will indirectly beneficially own 298,647 shares of common stock and 6,743,321 shares of non-voting common stock.
• Tomas Kiselak and Peter Harwin will each indirectly beneficially own 51,166 shares of common stock.
• Fairmount Funds Management LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest therein.
• The non-voting common stock is convertible into common stock on a 1-for-1 basis, subject to a 9.99% beneficial ownership limit, which can be adjusted to 19.99% with 61 days' notice.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to significant insider selling, even if pre-planned. While 10b5-1 plans are common, a large disposition by a 10% owner and directors can still be perceived as a reduction in conviction or a move to lock in gains, which might concern some investors. However, the existence of the 10b5-1 plan mitigates the negativity somewhat by indicating a lack of immediate, reactive selling.

Positives

• The sale is executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction rather than a discretionary sale based on immediate, non-public information.

Negatives

• A significant planned insider sale by a 10% owner and directors could be perceived negatively by the market, potentially signaling a reduction in direct equity exposure or a move to lock in gains.
• The disposition of 1,750,000 shares represents a substantial portion of the common stock previously held by the reporting entities.

Risks

• Potential negative market perception due to significant insider selling, which could exert downward pressure on the stock price.
• Reduced alignment of interests between the selling insiders and other shareholders due to a decrease in their common stock ownership.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the future transaction date. The use of a 10b5-1 plan implies a pre-determined selling strategy.

Management Comments

• Fairmount Funds Management LLC is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak.
• Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
• The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof... would beneficially own... no more than 9.99% of the outstanding shares of common stock... which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.
• Fairmount and Fairmount Healthcare Fund II LP may each be deemed a director by deputization of the Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of the Issuer and are also each a Managing Member of Fairmount.

Industry Context

Insider selling, particularly by significant shareholders and directors, is a common occurrence in the biotechnology industry, often driven by portfolio rebalancing, liquidity needs, or diversification strategies. The use of a 10b5-1 plan is standard practice for insiders to sell shares without being accused of trading on material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for insider sales is a standard practice across industries, including biotechnology, to mitigate concerns about trading on inside information.
• The conversion terms for non-voting common stock, including beneficial ownership limits, are typical mechanisms used by large institutional investors to manage their ownership percentages and avoid certain regulatory thresholds.

Corporate Governance

Related Party Transactions

• Disposition of 1,750,000 shares of common stock by Fairmount Funds Management LLC and its affiliates, where Peter Harwin and Tomas Kiselak are managing members and also directors of Apogee Therapeutics, Inc.

Stakeholder Impact

• Shareholders may view the significant planned insider selling as a signal, potentially leading to negative sentiment or downward pressure on the stock price. However, the 10b5-1 plan context might temper this.
• The transaction reflects a strategic decision by a significant investor group and its representatives on the board.

Key Dates

Recommendation

While the significant planned insider sale by Fairmount Funds Management and its associated directors might raise concerns, the transaction is scheduled for a future date and executed under a pre-arranged 10b5-1 plan. This suggests a systematic selling strategy rather than a reaction to new, negative material information. The reporting persons still retain substantial indirect ownership, including a large block of convertible non-voting common stock. Investors should monitor future filings and company performance, but this specific Form 4, given its 10b5-1 context and future date, does not immediately warrant a 'sell' recommendation unless other negative factors emerge. A 'hold' position is appropriate to observe further developments.

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Sale, Fairmount Funds Management, Tomas Kiselak, Peter Harwin, 10b5-1 Plan, Beneficial Ownership, Director Sale